Uveal melanoma (UM) is the most common primary ocular malignancy in adults in the Western world. UM with a mutation in , a spliceosome gene, is characterized by three or more structural changes of chromosome 1, 6, 8, 9, or 11. Also UM without a mutation in harbors similar chromosomal aberrations. Since, in addition to , mutations in and have also been observed in hematological malignancies, UM without a mutation-but with the characteristic chromosomal pattern-might harbor mutations in one of these genes. 42 UMs were selected based on their chromosomal profile and wildtype status. Sanger sequencing covering the (exon 2 and 7) hotspots and (exon 1 and 2) was performed on DNA extracted from tumor tissue. Data of three UM with an mutation was extracted from the The Cancer Genome Atlas (TCGA). Heterozygous in-frame deletions affecting amino acids 92-100 were detected in two UMs (5%) of 42 selected tumors and in three TGCA UM specimens. Both the UM with an mutation from our cohort and the UM samples from the TCGA showed more than four structural chromosomal aberrations including (partial) gain of chromosome 6 and 8, although in two TCGA UMs monosomy 3 was observed. Whereas in myelodysplastic syndrome predominantly missense mutations are described, the observed mutations in UM are all in-frame deletions of 8-9 amino acids. This suggests that the R625 missense SF3B1 mutations and SRSF2 mutations in UM are different compared to the spliceosome gene mutations in hematological cancers, and probably target a different, as yet unknown, set of genes involved in uveal melanoma etiology.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721539PMC
http://dx.doi.org/10.3390/cancers11081200DOI Listing

Publication Analysis

Top Keywords

uveal melanoma
12
mutations
8
spliceosome gene
8
chromosomal aberrations
8
ums selected
8
in-frame deletions
8
amino acids
8
mutations uveal
4
melanoma preference
4
preference in-frame
4

Similar Publications

Introduction: Uveal melanoma remains a disease with aggressive behavior and poor prognosis despite advances in clinical management. Because monotherapy with immune checkpoint inhibitors has led to limited improvement in response rates, combination with other agents that act on the biological basis of oncogenesis has been proposed as a possible therapeutic strategy.

Methods: We designed a phase 1b trial to test the safety and tolerability of selinexor in combination with immune checkpoint inhibitors in patients with advanced uveal melanoma.

View Article and Find Full Text PDF

Uveal melanoma (UM) poses a significant lethality, with approximately 50% of those developing metastases surviving less than one year. In the progression of UM, vasculogenic mimicry (VM) induced by hypoxia plays a pivotal role, which also partially explains the resistance of UM to anti-angiogenic therapies. Nevertheless, the crucial molecular mechanisms underlying VM in the progression of UM remain unclear.

View Article and Find Full Text PDF

NF1 encodes the multifunctional tumour suppressor protein, neurofibromin, which is best known for its causative role in Neurofibromatosis type 1 and in regulating MAPK signaling. Neurofibromin, in a context-specific manner, is involved in various tumorigenic processes, including those in melanocytes. This study investigated whether NF1 loss can collaborate with oncogenic GNAQ to promote melanoma in the dermis or eyes, where the G alpha q pathway is almost always activated.

View Article and Find Full Text PDF

BRM (SMARCA2) and BRG1 (SMARCA4) are mutually exclusive ATPase subunits of the mSWI/SNF (BAF) chromatin remodeling complex. BAF is an attractive therapeutic target because of its role in transcription, and mutations in the subunits of BAF are common in cancer and neurological disorders. Herein, we report the discovery of compound () as a potent allosteric inhibitor of the dual ATPase subunits from a high-throughput screening hit with a BRM IC of ∼27 μM.

View Article and Find Full Text PDF

Background: Proton beam therapy (PBT) has been gradually introduced for treating choroidal melanoma. This study systematically reviewed clinical reports to evaluate the efficacy and safety of PBT in choroidal melanoma patients.

Methods: This systematic review included all the primary studies involving PBT for choroidal melanoma patients through April 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!